Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Galectin Therapeutics Inc (GALT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Galectin's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.370 -0.130    -3.71%
02/05 - Closed. Currency in USD ( Disclaimer )
After Hours
3.230
-0.140
-4.154%
16:17:22 - Real-time Data
  • Volume: 250,229
  • Bid/Ask: 3.260 / 3.440
  • Day's Range: 3.230 - 3.540
Type:  Equity
Market:  United States
Galectin 3.370 -0.130 -3.71%

Galectin Therapeutics Inc Company Profile

 
Get an in-depth profile of Galectin Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

28

Equity Type

ORD

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Contact Information

Address 4960 Peachtree Industrial Boulevard Suite 240
Norcross, 30071
United States
Phone (678) 620-3186
Fax -

Top Executives

Name Age Since Title
Kary Eldred 50 2018 Independent Director
Kevin H. Mayo - - Member of the Scientific Board
Eric Lawitz - - Member of Clinical Advisory Board
Benjamin S. Carson 73 2023 Independent Director
Marc Rubin 69 2011 Independent Director
Gilbert F. Amelio 81 2009 Independent Director
Kevin D. Freeman 62 2011 Independent Vice Chairman of the Board
Anatole A. Klyosov 77 2000 Co-founder & Member of the Scientific Board
Stephen A. Harrison - - Member of Clinical Advisory Board
Brent Tetri - - Member of Clinical Advisory Board
Richard E. Uihlein 79 2017 Independent Chairman
Naga Chalasani - - Member of Clinical Advisory Board
Joel Lewis 54 2017 President, CEO & Director
Thomas D. Schiano - - Member of Clinical Advisory Board
Ram Subramanian - - Member of Clinical Advisory Board
Arun J. Sanyal - - Member of Clinical Advisory Board
Elissa J. Schwartz 53 2020 Independent Director
Richard A. Zordani 51 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GALT Comments

Write your thoughts about Galectin Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email